We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00114920
First Posted: June 21, 2005
Last Update Posted: February 19, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Graceway Pharmaceuticals, LLC
  Purpose

The primary purpose of this study is to evaluate the effectiveness in adults, of four different strengths of resiquimod gel applied to common wart(s) three times a week for twelve weeks.

A second purpose is to evaluate the safety of the drug.


Condition Intervention Phase
Warts Drug: Resiquimod Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single
Primary Purpose: Treatment
Official Title: A Three-Stage, Modified-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel for the Treatment of Common Warts in Adults

Resource links provided by NLM:


Further study details as provided by Graceway Pharmaceuticals, LLC:

Primary Outcome Measures:
  • Clearance of treated common wart(s)

Secondary Outcome Measures:
  • Partial clearance of treated common wart(s)
  • Wart recurrence

Estimated Enrollment: 88
Study Start Date: March 2004
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of common warts
  • Two forms of birth control

Exclusion Criteria:

  • Pregnant or breast feeding
  • Other types of wart(s), ie. plantar
  • Currently participating in another clinical study
  • Chronic viral hepatitis B or C
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00114920


Locations
United States, Indiana
Welborn Clinic
Evansville, Indiana, United States, 47713
Sponsors and Collaborators
Graceway Pharmaceuticals, LLC
  More Information

ClinicalTrials.gov Identifier: NCT00114920     History of Changes
Other Study ID Numbers: 1508-RESI
First Submitted: June 20, 2005
First Posted: June 21, 2005
Last Update Posted: February 19, 2007
Last Verified: November 2006

Keywords provided by Graceway Pharmaceuticals, LLC:
Wart(s)
Adults
Common Wart(s)

Additional relevant MeSH terms:
Warts
Papillomavirus Infections
DNA Virus Infections
Virus Diseases
Skin Diseases, Viral
Tumor Virus Infections
Skin Diseases, Infectious
Skin Diseases